Latest From Oncimmune Ltd.
Oncimmune has expanded its offering in the US with the launch of a blood-based liver cancer test, the second product to emerge from its EarlyCDT platform.
While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.
Oncimmune, the UK specialist in autoantibody-based tests for early cancer detection, has bullked up its human and financial resources with the appointment of a chief medical and strategy officer, and the closing of an investment tranche from its Chinese partner.
Oncimmune's commercialization of its early cancer diagnostic technology continues to gather pace as the firm enlists yet another distribution partner in Asia. The exclusive deal is for China, where the market opportunity for the company's EarlyCDT-Lung test is sizeable. The agreement also includes an equity investment by the Chinese partner in Oncimmune.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Oncimmune Ltd.
- Senior Management
Adam Hill, PhD, CEO
Matthew Hall, CFO
- Contact Info
Phone: 115 8231869
Clinical Sciences Bldg. Nottingham Hosp.
Nottingham, NG5 1PB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.